← EPO Patent Bulletin

CAR FOR USE IN THE TREATMENT OF HVG DISEASE

Search Report EP4671278A3 Kind: A3 Mar 18, 2026

Applicants

Medizinische Hochschule Hannover, Technische Universität Braunschweig

Inventors

JÄCKEL, Elmar, MOYAN, Fatih, HUST, Michael

Abstract

The invention provides a nucleic acid encoding an optimized and far potent chimeric antigen receptor having specificity for HLA-A*02. Also provided is its use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The encoded fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 in a recipient patient who is negative for HLA-A*02, i.e. the patient prior to transplantation does not express HLA-A*02. The encoded fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02.

IPC Classifications

A61P 37/06 20060101AFI20260206BHEP C07K 16/28 20060101ALI20260206BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR